Head-to-head evidence
Opicapone vs Trigel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: COMT · full Parkinson's Disease pipeline
Opicapone · Ongentys
Marketed by Amneal Pharmaceuticals and partners
NCT01568073 · Phase 3 · completed
The study randomized 600 participants and used triple masking with both placebo and entacapone comparator groups. Its primary clinical endpoint was change in daily OFF-time, but the registry reports only group means and no p-value or confidence interval, so whether the primary comparison was statistically successful cannot be determined.
Trigel · Lecigon
Developed by LobSor Pharmaceuticals AB and partners
NCT02448914 · Phase 1 · completed
This trial had randomized treatment order and an active comparator, and it reached a statistically significant result for its primary measure, but it was not blinded, enrolled only 11 patients, and measured drug blood levels rather than a clinical symptom or functional outcome, so it demonstrates pharmacokinetic exposure rather than a proven clinical benefit.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Opicapone's landscape · Trigel's landscape